Downregulation of histone deacetylase 1 by microRNA-520h contributes to the chemotherapeutic effect of doxorubicin

FEBS Letters

Volumn 588, Issue 1, 2014, Pages 184-191

  Shen, Qi ^a   Yao, Qinghua ^b   Sun, Jie ^a   Feng, Lifeng ^a   Lu, Haiqi ^a   Ma, Yanning ^a   Liu, Leiming ^a   Wang, Faliang ^a   Li, Jiaqiu ^a   Yue, Yongfang ^a   Jin, Hongchuan ^a   Wang, Xian ^a  

^a ZHEJIANG UNIVERSITY   (China)

^b CHINA MEDICAL UNIVERSITY   (China)

Author keywords

Doxorubicin; Drug resistance; Histone deacetylase 1; MicroRNA

Indexed keywords

DOXORUBICIN; HISTONE DEACETYLASE 1; HISTONE GAMMA H2AX; HISTONE H2AX; MICRORNA; MICRORNA 520H; UNCLASSIFIED DRUG;

ARTICLE; CANCER CELL CULTURE; CELL DEATH; CONTROLLED STUDY; DNA DAMAGE; DOUBLE STRANDED DNA BREAK; DOWN REGULATION; DRUG DNA INTERACTION; EPIGENETICS; GENE EXPRESSION; HUMAN; HUMAN CELL; PHARMACOLOGICAL BLOCKING; PRIORITY JOURNAL; PROTEIN DETERMINATION; PROTEIN EXPRESSION; PROTEIN STABILITY; UPREGULATION;

EID: 84891028265     PISSN: 00145793     EISSN: 18733468     Source Type: Journal    
DOI: 10.1016/j.febslet.2013.11.034     Document Type: Article

References (35)

1. A.D. Wagner, W. Grothe, J. Haerting, G. Kleber, A. Grothey, and W.E. Fleig Chemotherapy in advanced gastric cancer: a systematic review and meta-analysis based on aggregate data J. Clin. Oncol. 24 2006 2903 2909
2. G.J. Quigley, A.H. Wang, G. Ughetto, G. van der Marel, J.H. van Boom, and A. Rich Molecular structure of an anticancer drug-DNA complex: daunomycin plus d(CpGpTpApCpG) Proc. Natl. Acad. Sci. USA 77 1980 7204 7208
3. M.L. Petrillo, C.J. Newton, R.P. Cunningham, R.I. Ma, N.R. Kallenbach, and N.C. Seeman The ligation and flexibility of four-arm DNA junctions Biopolymers 27 1988 1337 1352
4. H. Lei, X. Wang, and C. Wu Early stage intercalation of doxorubicin to DNA fragments observed in molecular dynamics binding simulations J. Mol. Graph. Model. 38 2012 279 289
5. J.B. Chaires, N. Dattagupta, and D.M. Crothers Kinetics of the daunomycin-DNA interaction Biochemistry 24 1985 260 267
6. J. Taunton, C.A. Hassig, and S.L. Schreiber A mammalian histone deacetylase related to the yeast transcriptional regulator Rpd3p Science 272 1996 408 411
7. A.W. Bird et al. Acetylation of histone H4 by Esa1 is required for DNA double-strand break repair Nature 419 2002 411 415
8. K.M. Miller, J.V. Tjeertes, J. Coates, G. Legube, S.E. Polo, S. Britton, and S.P. Jackson Human HDAC1 and HDAC2 function in the DNA-damage response to promote DNA nonhomologous end-joining Nat. Struct. Mol. Biol. 17 2010 1144 1151
9. A. Scherpereel et al. Valproate-doxorubicin: promising therapy for progressing mesothelioma. A phase II study Eur. Respir. J. 37 2011 129 135
10. B.P. O'Neill, J.R. O'Fallon, J.D. Earle, J.P. Colgan, L.D. Brown, and R.L. Krigel Primary central nervous system non-Hodgkin's lymphoma: survival advantages with combined initial therapy? Int. J. Radiat. Oncol. Biol. Phys. 33 1995 663 673
11. C. Arce et al. A proof-of-principle study of epigenetic therapy added to neoadjuvant doxorubicin cyclophosphamide for locally advanced breast cancer PLoS One 1 2006 e98
12. P. Munster et al. Phase I trial of histone deacetylase inhibition by valproic acid followed by the topoisomerase II inhibitor epirubicin in advanced solid tumors: a clinical and translational study J. Clin. Oncol. 25 2007 1979 1985
13. L.A. Wittenburg, D.L. Gustafson, and D.H. Thamm Phase I pharmacokinetic and pharmacodynamic evaluation of combined valproic acid/doxorubicin treatment in dogs with spontaneous cancer Clin. Cancer Res. 16 2010 4832 4842
14. K.M. Tewey, T.C. Rowe, L. Yang, B.D. Halligan, and L.F. Liu Adriamycin-induced DNA damage mediated by mammalian DNA topoisomerase II Science 226 1984 466 468
15. S.C. Tsai, N. Valkov, W.M. Yang, J. Gump, D. Sullivan, and E. Seto Histone deacetylase interacts directly with DNA topoisomerase II Nat. Genet. 26 2000 349 353
16. L. Magnaghi-Jaulin, and C. Jaulin Histone deacetylase activity is necessary for chromosome condensation during meiotic maturation in Xenopus laevis Chromosome Res. 14 2006 319 332
17. N.T. Chen, C.Y. Wu, C.Y. Chung, Y. Hwu, S.H. Cheng, C.Y. Mou, and L.W. Lo Probing the dynamics of doxorubicin-DNA intercalation during the initial activation of apoptosis by fluorescence lifetime imaging microscopy (FLIM) PLoS One 7 2012 e44947
18. X. Gao, L. Niu, and X. Su Detection of DNA via the fluorescence quenching of Mn-doped ZnSe D-dots/doxorubicin/DNA ternary complexes system J. Fluoresc. 22 2012 103 109
19. S.J. Froelich-Ammon, M.W. Patchan, N. Osheroff, and R.B. Thompson Topoisomerase II binds to ellipticine in the absence or presence of DNA. Characterization of enzyme-drug interactions by fluorescence spectroscopy J. Biol. Chem. 270 1995 14998 15004
20. N.Y. Frank et al. ABCB5-mediated doxorubicin transport and chemoresistance in human malignant melanoma Cancer Res. 65 2005 4320 4333
21. M.A. Glozak, and E. Seto Histone deacetylases and cancer Oncogene 26 2007 5420 5432
22. W. Weichert et al. Association of patterns of class I histone deacetylase expression with patient prognosis in gastric cancer: a retrospective analysis Lancet Oncol. 9 2008 139 148
23. M. Nakagawa et al. Expression profile of class I histone deacetylases in human cancer tissues Oncol. Rep. 18 2007 769 774
24. J.H. Choi, H.J. Kwon, B.I. Yoon, J.H. Kim, S.U. Han, H.J. Joo, and D.Y. Kim Expression profile of histone deacetylase 1 in gastric cancer tissues Jpn. J. Cancer Res. 92 2001 1300 1304
25. X. Wang, and J.J. Hayes Acetylation mimics within individual core histone tail domains indicate distinct roles in regulating the stability of higher-order chromatin structure Mol. Cell Biol. 28 2008 227 236
26. C.A. Austin, and K.L. Marsh Eukaryotic DNA topoisomerase II beta Bioessays 20 1998 215 226
27. S. Volinia et al. A microRNA expression signature of human solid tumors defines cancer gene targets Proc. Natl. Acad. Sci. USA 103 2006 2257 2261
28. G.A. Calin, and C.M. Croce MicroRNA-cancer connection: the beginning of a new tale Cancer Res. 66 2006 7390 7394
29. E.K. Lam et al. A microRNA contribution to aberrant Ras activation in gastric cancer Am. J. Transl. Res. 3 2011 209 218
30. M. Kato et al. The mir-34 microRNA is required for the DNA damage response in vivo in C. elegans and in vitro in human breast cancer cells Oncogene 28 2009 2419 2424
31. J. Pothof et al. MicroRNA-mediated gene silencing modulates the UV-induced DNA-damage response EMBO J. 28 2009 2090 2099
32. J. Ma, C. Dong, and C. Ji MicroRNA and drug resistance Cancer Gene. Ther. 17 2010 523 531
33. M. Karaayvaz, H. Zhai, and J. Ju MiR-129 promotes apoptosis and enhances chemosensitivity to 5-fluorouracil in colorectal cancer Cell Death Dis. 4 2013 e659
34. O. Kovalchuk, J. Filkowski, J. Meservy, Y. Ilnytskyy, V.P. Tryndyak, V.F. Chekhun, and I.P. Pogribny Involvement of microRNA-451 in resistance of the MCF-7 breast cancer cells to chemotherapeutic drug doxorubicin Mol. Cancer Ther. 7 2008 2152 2159
35. L. Feng et al. Histone deacetylase 3 inhibits expression of PUMA in gastric cancer cells J. Mol. Med. (Berl) 91 2013 49 58